Peritoneal Injury in patients with peritoneal dialysis
Conditions
Interventions
Oral administration of 600mg/day (200mgmg t.i.d) pyridoxamine for 6 months
Sponsors
Juntendo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Stablr PD more than 3months after the starting PD
Exclusion criteria
Exclusion criteria: >Combined therapy with PD and hemodialysis >Severe liver disease >Previous severe adverse effect and all allergy >Participating other clinical stadies >Malignancy, or less than 3-years after treatment of the cancer >Less than 6-months from previous cardiovascular disease (myocaridial infarction and apoplexy) >More than 8 years PD, or having enca psulating peritoneal sclerosis. >Peripheral arterial disease (more than class 2 of Fontaine classification). >Uncontrolled hypertension (more than 180mmHg of systolic BP and 120mmHg of diastolic BP). >HbA1c >8.0%. >Severe anemia (Hb <9.0g/dl) >Using aminophylline, theophylline, cholinetheophylline, levodopa, pyridoxa l, pyridoxine, and other vitamin B6 agen ts within 4 weeks. >Expected pregnancy within 1 year. >Others judged to be excluded by doc tors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of D/P creatinine and ultrafiltration rate in peritoneal equilibrium test and net ultrafiltraion volume in 24-hours 3 months after pyridoxamine administration. Changes of pyridoxamine, pyridoxal and pyridoxine in peritoneal effluent and sera 3 months after pyridoxamine administration. | — |
Countries
Japan
Contacts
Public ContactChieko Hamada
Juntendo Hospital Division of Nephrology
Outcome results
None listed